Bulevirtide als erster spezifischer Wirkstoff gegen Hepatitis-D-Virusinfektionen – Mechanismus und klinische Wirkung

Blocking the cell entry of pathogens is a suitable approach to prevent new infections. However, the therapeutic use of entry inhibitors in chronically infected patients has had limited success. For the treatment of chronic hepatitis D virus (HDV) infections, a promising agent based on this mode of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkongolo, Shirin, Hollnberger, Julius, Urban, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Leitthema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813823/
https://www.ncbi.nlm.nih.gov/pubmed/35028672
http://dx.doi.org/10.1007/s00103-022-03486-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813823/
https://www.ncbi.nlm.nih.gov/pubmed/35028672
http://dx.doi.org/10.1007/s00103-022-03486-2

Ejemplares similares